User login
Key clinical point: Dimethyl fumarate (DMF) may slow down cognitive impairment in patients with relapsing-remitting multiple sclerosis (RRMS).
Major finding: Of 34 patients with cognitive impairment at baseline, 55.9% of patients did not show evidence of cognitive worsening at 2 years.
Study details: This prospective single-arm study enrolled patients with RRMS (n=217) treated with DMF for 2 years.
Disclosures: This study was funded by Biogen. The authors reported relationships with multiple pharmaceutical companies.
Citation: Amato MP et al. Neurol Sci. 2020 May 01. doi: 10.1007/s10072-020-04320-w.
Key clinical point: Dimethyl fumarate (DMF) may slow down cognitive impairment in patients with relapsing-remitting multiple sclerosis (RRMS).
Major finding: Of 34 patients with cognitive impairment at baseline, 55.9% of patients did not show evidence of cognitive worsening at 2 years.
Study details: This prospective single-arm study enrolled patients with RRMS (n=217) treated with DMF for 2 years.
Disclosures: This study was funded by Biogen. The authors reported relationships with multiple pharmaceutical companies.
Citation: Amato MP et al. Neurol Sci. 2020 May 01. doi: 10.1007/s10072-020-04320-w.
Key clinical point: Dimethyl fumarate (DMF) may slow down cognitive impairment in patients with relapsing-remitting multiple sclerosis (RRMS).
Major finding: Of 34 patients with cognitive impairment at baseline, 55.9% of patients did not show evidence of cognitive worsening at 2 years.
Study details: This prospective single-arm study enrolled patients with RRMS (n=217) treated with DMF for 2 years.
Disclosures: This study was funded by Biogen. The authors reported relationships with multiple pharmaceutical companies.
Citation: Amato MP et al. Neurol Sci. 2020 May 01. doi: 10.1007/s10072-020-04320-w.